clinical trial · NCT07516561
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
Apsen Farmaceutica S.A.·phase3·not yet recruiting·n = 336
Alopecia, AndrogeneticAPSMNF 1APSMNF 2Eniagor®
brief summary
The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.
started
Jul 7, 2026
primary completion
Aug 2, 2029
completion
Aug 2, 2029
last updated
Apr 13, 2026
official title
Phase III Randomized, Multicenter, Double-blind, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol